NERV

Minerva Neurosciences, Inc. (NASDAQ:NERV) is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Waltham, Massachusetts. Originally incorporated as Cyrenaic Pharmaceuticals, Inc., the company changed its name to Minerva Neurosciences in 2013 and went public in July 2014. The company focuses on developing treatments for central nervous system diseases, with its lead drug candidate roluperidone targeting schizophrenia symptoms. Minerva operates as a development-stage company without commercial products, relying on partnerships and licensing agreements to advance its pipeline.